Olaparib (Lynparza) has been TGA approved for the treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer that has progressed following prior therapy including a new hormonal agent such as abiraterone and enzalutamide. Evidence for the approval is largely based on the PROfound study, published in the NEJM last year, which found the PARP inhibitor ...
PARP inhibitor now approved for BRCA-mutated prostate cancer
By Mardi Chapman
6 May 2021